41 – 50 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 1996
-
Mark
Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
(
- Contribution to journal › Article
- 1994
-
Mark
Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin(TM)). An experimental investigation in healthy volunteers
(
- Contribution to journal › Article
-
Mark
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis : A comparison with low molecular weight heparin
(
- Contribution to journal › Article
- 1993
-
Mark
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
(
- Contribution to journal › Article
- 1990
-
Mark
Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement
(
- Contribution to journal › Article
-
Mark
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats
(
- Contribution to journal › Article
- 1989
-
Mark
Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery
(
- Contribution to journal › Article
-
Mark
Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?
(
- Contribution to journal › Article
- 1988
-
Mark
Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement
(
- Contribution to journal › Article
- 1987
-
Mark
Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers
(
- Contribution to journal › Article